New cell therapy aims to tame Graft-Versus-Host disease

NCT ID NCT06920199

Recruiting now Disease control Sponsor: Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase trial tests whether infusing specially prepared donor immune cells (Treg cells) along with low-dose interleukin-2 can safely treat refractory chronic graft-versus-host disease (cGVHD), a serious complication after stem cell transplants. The study will enroll 18 adults aged 18-70 who have moderate to severe cGVHD that hasn't responded to steroids. The main goal is to check for dangerous side effects within 28 days of treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: donor-derived Treg cells combined with interleukin-2
What this could lead to: If it works, this could offer a new treatment option for patients with hard-to-treat chronic graft-versus-host disease.
What could go wrong: This is a very early, small trial (18 people) focused on safety, not proof of effectiveness. The treatment may cause serious side effects like cytokine release syndrome.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CGVHD are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Bronchiolitis Obliterans Syndrome chronic graft versus host disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CGVHD

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Shanghai General Hospital
RECRUITING

Shanghai, 200080, China

Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.